a public good project by the
Synthesis
Company
of California

© 2026

Chloe Orkin | doi.page

0 works0 citations0 h-index

Chloe Orkin

Queen Mary University of London(GB)Barts Health NHS Trust(GB)University Hospitals of Leicester NHS Trust(GB)

Publications by Year

Research Areas

HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, HIV Research and Treatment, HIV-related health complications and treatments, Hepatitis C virus research

Most-Cited Works

→ Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022(2022)2,099 cited
→ Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials(2019)732 cited
→ Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy(2014)589 cited
→ Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study(2013)542 cited
→ Monkeypox(2022)526 cited
→ Mpox in people with advanced HIV infection: a global case series(2023)462 cited

→ Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection(2020)

443 cited

→ Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals(2010)426 cited

→ Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study(2010)409 cited

→ Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial(2017)370 cited